Abstract
Multiple ligand efficient fragment inhibitors of protein kinase B were identified through a combined in silico compound screen and high-throughput crystallographic analysis of protein-ligand structures. A well-validated apo-PKBPKA chimeric protein provided a convenient platform for high-throughput crystallography by soaking of inhibitors, and a method for the determination of PKB-ligand structures was developed to support inhibitor development. Pyrazole and azaindole fragment hits with micromolar activity were rapidly progressed to nanomolar inhibitors of PKB with activity in cells using crystallographic analysis of inhibitor binding modes to guide medicinal chemistry. Compounds with selectivity for PKB over PKA and other kinases were identified by this approach, resulting in potent inhibitors with in vivo activity through both oral and systemic administration, and suitable for further development.
Current Topics in Medicinal Chemistry
Title: Fragment-Based Discovery of Inhibitors of Protein Kinase B
Volume: 9 Issue: 18
Author(s): Thomas G. Davies, Steven J. Woodhead and Ian Collins
Affiliation:
Abstract: Multiple ligand efficient fragment inhibitors of protein kinase B were identified through a combined in silico compound screen and high-throughput crystallographic analysis of protein-ligand structures. A well-validated apo-PKBPKA chimeric protein provided a convenient platform for high-throughput crystallography by soaking of inhibitors, and a method for the determination of PKB-ligand structures was developed to support inhibitor development. Pyrazole and azaindole fragment hits with micromolar activity were rapidly progressed to nanomolar inhibitors of PKB with activity in cells using crystallographic analysis of inhibitor binding modes to guide medicinal chemistry. Compounds with selectivity for PKB over PKA and other kinases were identified by this approach, resulting in potent inhibitors with in vivo activity through both oral and systemic administration, and suitable for further development.
Export Options
About this article
Cite this article as:
Davies G. Thomas, Woodhead J. Steven and Collins Ian, Fragment-Based Discovery of Inhibitors of Protein Kinase B, Current Topics in Medicinal Chemistry 2009; 9 (18) . https://dx.doi.org/10.2174/156802609790102419
DOI https://dx.doi.org/10.2174/156802609790102419 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Composite Lymphomas: A Challenging Entity
Current Cancer Therapy Reviews Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Current Immunology Reviews (Discontinued) One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Tackling COVID-19 Through Ayurveda: A Review on the Herbs of Recommended Indian Remedies
Current Traditional Medicine Structure and Function of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
Current Drug Metabolism Development Course and an Application Strategy for Induced Pluripotent Stem Cells in Regenerative Medicine
Current Stem Cell Research & Therapy Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Molecular Chaperone Hsp90 as a Target for Oxidant-Based Anticancer Therapies
Current Medicinal Chemistry New Candidate Genes for Lack of Sensitivity to Therapy in Pediatric Leukemias
Current Cancer Drug Targets Monoclonal Antibodies in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Chlorambucil Cytotoxicity Reduction in Rats Through Bone Marrow, An In vivo Study
Anti-Cancer Agents in Medicinal Chemistry Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Current Medicinal Chemistry Update on MDS Therapy: From Famine to Feast
Cardiovascular & Hematological Agents in Medicinal Chemistry